Literature DB >> 30779719

The Cost-Effectiveness of Interventions to Increase Utilization of Prone Positioning for Severe Acute Respiratory Distress Syndrome.

Cameron M Baston1,2, Norma B Coe1,3,4,5, Claude Guerin6, Jordi Mancebo7, Scott Halpern1,2,3,4.   

Abstract

OBJECTIVES: Despite strong evidence supporting proning in acute respiratory distress syndrome, few eligible patients receive it. This study determines the cost-effectiveness of interventions to increase utilization of proning for severe acute respiratory distress syndrome.
DESIGN: We created decision trees to model severe acute respiratory distress syndrome from ICU admission through death (societal perspective) and hospital discharge (hospital perspective). We assumed patients received low tidal volume ventilation. We used short-term outcome estimates from the PROSEVA trial and longitudinal cost and benefit data from cohort studies. In probabilistic sensitivity analyses, we used distributions for each input that included the fifth to 95th percentile of its CI.
SETTING: ICUs that care for patients with acute respiratory distress syndrome.
SUBJECTS: Patients with moderate to severe acute respiratory distress syndrome.
INTERVENTIONS: The implementation of a hypothetical intervention to increase the appropriate utilization of prone positioning.
MEASUREMENTS AND MAIN RESULTS: In the societal perspective model, an intervention that increased proning utilization from 16% to 65% yielded an additional 0.779 (95% CI, 0.088-1.714) quality-adjusted life years at an additional long-term cost of $31,156 (95% CI, -$158 to $92,179) (incremental cost-effectiveness ratio = $38,648 per quality-adjusted life year [95% CI, $1,695-$98,522]). If society was willing to pay $100,000 per quality-adjusted life year, any intervention costing less than $51,328 per patient with moderate to severe acute respiratory distress syndrome would represent good value. From a hospital perspective, the intervention yielded 0.072 (95% CI, 0.008-0.147) more survivals-to-discharge at a cost of $5,242 (95% CI, -$19,035 to $41,019) (incremental cost-effectiveness ratio = $44,615 per extra survival [95% CI, -$250,912 to $558,222]). If hospitals were willing to pay $100,000 per survival-to-discharge, any intervention costing less than $5,140 per patient would represent good value.
CONCLUSIONS: Interventions that increase utilization of proning would be cost-effective from both societal and hospital perspectives under many plausible cost and benefit assumptions.

Entities:  

Mesh:

Year:  2019        PMID: 30779719      PMCID: PMC6383780          DOI: 10.1097/CCM.0000000000003617

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  Hospital-Level Availability of Prone Positioning in Massachusetts ICUs.

Authors:  Anica C Law; Natalia Forbath; Sharon O'Donoghue; Jennifer P Stevens; Allan J Walkey
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

Review 2.  Positioning for acute respiratory distress in hospitalised infants and children.

Authors:  Abhishta P Bhandari; Daniel A Nnate; Lenny Vasanthan; Menelaos Konstantinidis; Jacqueline Thompson
Journal:  Cochrane Database Syst Rev       Date:  2022-06-06

3.  Procedure Codes for Intubated Prone Positioning: A Turn for the Better.

Authors:  Anica C Law; Nicholas A Bosch; Allan J Walkey
Journal:  Ann Am Thorac Soc       Date:  2022-10

Review 4.  Prone Positioning of Older Adults with COVID-19: A Brief Review and Proposed Protocol.

Authors:  D E Brazier; N Perneta; F E Lithander; E J Henderson
Journal:  J Frailty Aging       Date:  2022

Review 5.  Prone position for acute respiratory failure in adults.

Authors:  Roxanna Bloomfield; David W Noble; Alexis Sudlow
Journal:  Cochrane Database Syst Rev       Date:  2015-11-13

6.  Cost-Effectiveness of Four Financial Incentive Programs for Smoking Cessation.

Authors:  Louise B Russell; Kevin G Volpp; Pui L Kwong; Benjamin S Cosgriff; Michael O Harhay; Jingsan Zhu; Scott D Halpern
Journal:  Ann Am Thorac Soc       Date:  2021-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.